Physician profile
Tony Wong
NPI 1831274422
$34,372.80
in general payments reported to CMS, 2019-2025
76 companies · $3,624 in 2025
The $3,624 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,237 · 2020: $4,957 · 2021: $6,676 · 2022: $5,982 · 2023: $4,523 · 2024: $4,373 · 2025: $3,624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,514.00 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $6,248.52 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $4,862.19 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $2,543.99 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $2,195.65 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,039.78 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Merck Sharp & Dohme LLC | $1,604.74 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Lilly USA, LLC | $1,362.91 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $1,241.16 | 2021-2025 | |
| Abbvie INC. | $1,222.69 | 2019-2025 | Linzess, Viberzi, Creon |
| Esperion Therapeutics, INC. | $1,117.67 | 2020-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $853.96 | 2019-2025 | Xifaxan |
| Amgen INC. | $797.62 | 2019-2025 | Repatha, Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $774.84 | 2019-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $746.74 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $709.39 | 2019-2025 |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $639.13 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $510.79 | 2019-2023 | Lifevest |
| Sanofi-Aventis U.S. LLC | $324.26 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $318.51 | 2019-2025 | Linzess |
| Electromed, INC. | $310.85 | 2022-2025 | Smartvest |
| Nestle Healthcare Nutrition INC. | $273.62 | 2021-2023 | |
| Avanir Pharmaceuticals, INC. | $254.71 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $254.69 | 2023-2025 | Nuedexta, Rexulti |
| Allergan, INC. | $196.43 | 2019-2020 | |
| Exact Sciences Corporation | $172.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $161.60 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $159.14 | 2022-2025 | Zoryve |
| Arbor Pharmaceuticals, INC. | $144.87 | 2019-2020 | |
| Insmed, INC. | $144.67 | 2022-2025 | Arikayce |
| Hikma Pharmaceuticals USA | $121.78 | 2019-2023 | Mitigare |
| Astellas Pharma US INC | $111.68 | 2020-2025 | Veozah |
| Dexcom, INC. | $105.25 | 2023-2025 | Dexcom G6 Transmitter |
| Lexicon Pharmaceuticals, INC. | $102.82 | 2023-2024 | Inpefa |
| Gilead Sciences, INC. | $97.74 | 2020-2022 | |
| Insulet Corporation | $96.58 | 2021-2022 | |
| Philips North America LLC | $86.09 | 2023-2025 | Vest Therapy Und |
| Corcept Therapeutics | $85.28 | 2021-2023 | Korlym |
| Xeris Pharmaceuticals, INC. | $82.56 | 2024-2025 | Gvoke Hypopen |
| Ibsa Pharma INC. | $78.27 | 2023 | Tirosint, Licart |
| Boston Scientific Corporation | $76.24 | 2022 | |
| Irhythm Technologies, INC. | $75.10 | 2020-2023 | Zio Xt Patch |
| Biohaven Pharmaceutical Holding Company LTD. | $74.89 | 2022 | |
| Vifor Pharma, INC. | $56.49 | 2019 | |
| Radius Health, INC. | $56.20 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $55.41 | 2021 | |
| Sumitomo Pharma America, INC. | $49.34 | 2023 | Aptiom |
| Sunovion Pharmaceuticals INC. | $48.29 | 2022 | |
| Heartflow, INC. | $47.86 | 2025 | |
| Sk Life Science, INC. | $47.08 | 2025 | |
| Aimmune Therapeutics, INC. | $42.04 | 2025 | Zenpep |
| Inari Medical, INC. | $41.80 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Agepha Pharma Fz LLC | $41.01 | 2025 | Lodoco |
| Genzyme Corporation | $31.86 | 2023 | |
| Ani Pharmaceuticals, INC. | $31.58 | 2025 | Purified Cortrophin Gel |
| Madrigal Pharmaceuticals | $31.12 | 2025 | Rezdiffra |
| Kyowa Kirin, INC. | $26.35 | 2022 | |
| Rgh Enterprises LLC | $26.12 | 2024 | |
| Grt US Holding, INC. | $25.37 | 2021 | |
| Edwards Lifesciences Corporation | $24.76 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $24.44 | 2021 | |
| Phathom Pharmaceuticals, INC. | $23.99 | 2024 | Voquezna |
| Horizon Therapeutics Plc | $20.66 | 2023 | Krystexxa |
| Medtronic, INC. | $20.40 | 2021 | |
| Stryker Corporation | $19.93 | 2025 | Aequalis Perform |
| Regeneron Healthcare Solutions, INC. | $19.39 | 2019 | |
| Circassia INC. | $19.26 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $18.17 | 2021 | |
| Organogenesis INC. | $17.98 | 2024 | |
| Daiichi Sankyo INC. | $17.71 | 2019 | |
| Nabriva Therapeutics, Plc | $16.73 | 2022 | |
| Lifescan, INC. | $16.42 | 2021 | |
| Seqirus USA INC | $16.35 | 2025 | Fluad, Flucelvax |
| Medicomp INC | $15.54 | 2021 | |
| Mylan Specialty L.P. | $15.11 | 2019 | |
| Shionogi INC | $13.64 | 2019 | |
| Smith+Nephew, INC. | $12.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.